Teriparatide (Forteo, also available in generic form) is a recombinant form of parathyroid hormone, used in the treatment of some forms of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.
The most commonly reported side effects are nausea, leg cramps and dizziness. The main risk of teriparatide is an increased risk of osteosarcoma, at least as seen in rat studies. It should be noted that, unlike humans, rat bones grow for their entire life. The tumors found in the rat studies were located on the end of the bones which grew after the injections began. Cases of bone tumor and osteosarcoma have been reported rarely in the postmarketing period.
Read More: Teriparatide Acetate price
No comments:
Post a Comment